Ardelyx Inc. (ARDX)
Ardelyx Tops Estimates as Sales Surge
Ardelyx (ARDX -8.10%), a biopharmaceutical company specializing in innovative treatments for gastrointestinal and kidney diseases, released its fourth-quarter earnings report on Feb. 20. The release highlighted considerable progress in the company's commercialization of its two approved drugs, Ibsrela and Xphozah.
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Ardelyx (ARDX) Meets Q4 Earnings Estimates
Ardelyx (ARDX) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.12 per share a year ago.
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?
Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
Ardelyx (ARDX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
Ardelyx lost a lawsuit against Medicare, impacting XPHOZAH's revenue potential, with no other major prospects in its pipeline. CMS's decision to move XPHOZAH to the bundled payment system significantly reduces its revenue, forcing Ardelyx to negotiate complex reimbursements. The Kidney PATIENT Act, if passed, will delay the inclusion of oral-only ESRD drugs in the bundled payment system, benefiting Ardelyx until 2027.
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
Ardelyx's Q3 revenue grew to $98 million, with strong Xphozah sales despite CMS's recent bundling ruling impacting future reimbursement. The CMS lawsuit dismissal affected Xphozah's reimbursement prospects, creating significant regulatory uncertainty and limiting Ardelyx's revenue control. Ibsrela faces substantial competition in the IBS-C market, with lofty revenue projections likely overstating its realistic market share.
Ardelyx, Inc. (ARDX) Q3 2024 Earnings Call Transcript
Ardelyx, Inc. (NASDAQ:ARDX ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Caitlin Lowie - Vice President of Corporate Communications & Investor Relations Michael Raab - President & Chief Executive Officer Eric Foster - Chief Commercial Officer Justin Renz - Chief Financial Officer & Chief Operations Officer Conference Call Participants Louise Chen - Cantor Fitzgerald Dennis Ding - Jefferies Roanna Ruiz - Leerink Partners Laura Chico - Wedbush Joseph Thome - TD Cowen Ryan Deschner - Raymond James Matt Kaplan - Ladenburg Thalmann Chris Raymond - Piper Sandler & Co. Operator Good afternoon, ladies and gentlemen and welcome to the Ardelyx Third Quarter 2024 Earnings Call. Our host for today's call is Caitlin Lowie, Vice President of Corporate Communications and Investor Relations at Ardelyx.
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics
The headline numbers for Ardelyx (ARDX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Ardelyx (ARDX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.03 per share a year ago.
Earnings Preview: Ardelyx (ARDX) Q3 Earnings Expected to Decline
Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Ardelyx (ARDX) Could be Great Choice for a Bottom Fisher
After losing some value lately, a hammer chart pattern has been formed for Ardelyx (ARDX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
